Verrica Pharmaceuticals Business Summary

Verrica Pharmaceuticals Inc. (VRCA) is a commercial-stage dermatology therapeutics company that generates revenue primarily through the sale of YCANTH (VP-102), the first and only FDA-approved treatment for molluscum contagiosum. The company operates through a dual-track business model combining direct U.S. commercialization with strategic international licensing, such as its partnership with Torii Pharmaceutical for the Japanese market. Its primary business segments include viral dermatology, targeting molluscum and common warts, and dermatologic oncology, focused on basal cell carcinoma through its licensed oncolytic peptide VP-315. Verrica competes directly with dermatology-focused firms such as Arcutis Biotherapeutics, Botanix Pharmaceuticals, and Incyte. As of 2026, Verrica maintains a dominant market position as the sole provider of an FDA-cleared prescription therapy for molluscum, while aggressively expanding into the common warts segment to capture a larger share of the medical dermatology market. Founded in 2013 by Matthew Davidson, Verrica is currently led by President and CEO Jayson Rieger, PhD, MBA, who brings extensive experience from PBM Capital and Lytix Biopharma. The executive team was further strengthened in February 2026 with the appointment of Chris Chapman as Chief Commercial Officer, a veteran with over 25 years of experience at Dermavant, Galderma, and Pfizer. Other key leaders include Chief Operating Officer David Zawitz, Chief Medical Officer Noah Rosenberg, and Interim CFO John Kirby. The company is backed by high-profile institutional investors including Perceptive Advisors and Armistice Capital, with the board of directors chaired by Paul B. Manning, the founder of PBM Capital. The leadership team’s pedigree is characterized by a deep background in pharmaceutical drug development and successful product launches, positioning the firm for its next phase of global commercial scaling.